Vimarsana
Biggest News Aggregation in the World

Page 4 - Randomized Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Randomized Phase Today - Breaking & Trending Today

Dana-Farber Researchers to Present Findings at 2023 San Antonio Breast Cancer Symposium - Vimarsana News

Dana-Farber Researchers to Present Findings at 2023 San Antonio Breast Cancer Symposium

Published: December 6, 2023

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 46th annual San Antonio Breast Cancer Symposium, December 5–9, 2023.

Source: onclive.com
Related Topics:
San AntonioUnited StatesHeather ParsonsPaolo TarantinoNolan PriedigkeitTrastuzumab DeruxtecanAdrienne WaksSarah SammonsDana Farber Cancer InstituteDuke Cancer CenterSan Antonio Breast Cancer SymposiumRandomized PhaseCombined With AvelumabMetastatic BreastProposed Therapeutic ExploitationReal World ActivityMetastatic Breast CancerDuke CancerBiopsy DeterminationBreast CancerResults FromNovel EpigenomicCumulative Incidence
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent… - Vimarsana News

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent…

Published: December 5, 2023

Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial Indicate That Prior Use of Trilaciclib with Cytotoxic…

Source: biztoc.com
Related Topics:
Randomized PhaseTriple Negative Breast CancerTrial Indicate That Prior UseHighly CorrelatedImproved Long Term SurvivalSubsequent Anticancer TherapiesLong Term Survival Also ObservedPatients Who Received Prior TrilaciclibCytotoxic TherapyReaking News
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy - Vimarsana News

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

Published: December 5, 2023

- Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer Trial Indicate That Prior Use of Trilaciclib with Cytotoxic Chemotherapy is Highly Correlated to Improved...

Source: marketscreener.com
Related Topics:
San AntonioUnited StatesRaj MalikResearch Triangle ParkAmerican Cancer SocietyTherapeutics IncExchange CommissionInvestor Relations Corporate CommunicationsRandomized PhaseTriple Negative Breast CancerTrial Indicate That Prior UseHighly CorrelatedImproved Long Term SurvivalSubsequent Anticancer TherapiesLong Term Survival Also ObservedPatients Who Received Prior TrilaciclibCytotoxic TherapyWere UnableReceive Subsequent Anticancer TherapyAntonio Breast Cancer SymposiumChief Medical OfficerPrivate Securities Litigation Reform ActInvestor Relations
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference - Vimarsana News

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

Published: December 4, 2023

Initial interim landmark data analysis to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, on Saturday, February 3, 2024 at 4:20 p.m. ET ...

Source: marketscreener.com
Related Topics:
United StatesKatherine SmithArshadm KhananiJulian PeiReno School Of MedicineClinical Associate Professor At University Of NevadaCorporate CommunicationsClinical Research At Sierra Eye AssociatesPrincipal InvestigatorMolecular TherapeuticsDose ExpansionDegeneration Presentation DetailsInterim ResultsRandomized PhaseExpansion StageHigh Need PatientsClinical ResearchSierra Eye AssociatesClinical Associate ProfessorReno SchoolScientific PresentationsTherapeutic Vector EvolutionNobel Prize WinningInvestor Relations
Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study - Vimarsana News

Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study

Published: December 1, 2023

Mark A. Socinski, MD, reviews data from the PAPILLON study presented at ESMO 2023 on amivantamab plus chemotherapy vs chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Source: onclive.com
Related Topics:
Marka SocinskiFirst Line TreatmentMutated AdvancedPrimary Results FromRandomized PhasePapillon StudyPapillon TrialAdvanced Non Small Cell Lung CancerAdvanced NsclcEgfr Exon 20 Insertion Mutated Advanced NsclcEgfr Exon 20 Insertion MutationsBispecific AntibodySafety ProfileAmivantamab Safety Provile